Armata Pharmaceuticals, Inc.2025财年第一财季实现净利润-6.53百万美元，同比增加73.90%

市场透视2025-05-23

5月23日，Armata Pharmaceuticals, Inc.（ARMP.US）公布财报，公告显示公司2025财年第一财季净利润为-6.53百万美元，同比增加73.90%；其中营业收入为491000.00美元，同比减少49.17%，每股基本收益为-0.18美元。从资产负债表来看，Armata Pharmaceuticals, Inc.（ARMP.US）总负债1.41亿美元，其中短期债务...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2537147923?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-23 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2537147923","market":"us","top_or_hot":-1,"title":"Armata Pharmaceuticals, Inc.2025财年第一财季实现净利润-6.53百万美元，同比增加73.90%","media":"市场透视","content":"<div>\n<p>5月23日，Armata Pharmaceuticals, Inc.（ARMP.US）公布财报，公告显示公司2025财年第一财季净利润为-6.53百万美元，同比增加73.90%；其中营业收入为491000.00美元，同比减少49.17%，每股基本收益为-0.18美元。从资产负债表来看，Armata Pharmaceuticals, Inc.（ARMP.US）总负债1.41亿美元，其中短期债务...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523000159a6e914a6&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Armata Pharmaceuticals, Inc.2025财年第一财季实现净利润-6.53百万美元，同比增加73.90%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArmata Pharmaceuticals, Inc.2025财年第一财季实现净利润-6.53百万美元，同比增加73.90%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-23 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523000159a6e914a6&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月23日，Armata Pharmaceuticals, Inc.（ARMP.US）公布财报，公告显示公司2025财年第一财季净利润为-6.53百万美元，同比增加73.90%；其中营业收入为491000.00美元，同比减少49.17%，每股基本收益为-0.18美元。从资产负债表来看，Armata Pharmaceuticals, Inc.（ARMP.US）总负债1.41亿美元，其中短期债务...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523000159a6e914a6&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARMP","symbol_name":"Armata Pharmaceuticals, Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523000159a6e914a6&s=b","article_id":"2537147923","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523000159a6e914a6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2537147923","pubTimestamp":1747929640,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"5月23日，Armata Pharmaceuticals, Inc.公布财报，公告显示公司2025财年第一财季净利润为-6.53百万美元，同比增加73.90%；其中营业收入为491000.00美元，同比减少49.17%，每股基本收益为-0.18美元。机构评级：截至2025年5月23日，当前有1家机构对Armata Pharmaceuticals, Inc.目标价做出预测，其中目标均价为9.00美元，其中最低目标价为9.00美元，最高目标价为9.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"ARMP":"Armata Pharmaceuticals, Inc."},"translate_title":"Armata Pharmaceuticals, Inc. achieved net profit of-US $6.53 million in the first fiscal quarter of fiscal year 2025, a year-on-year increase of 73.90%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARMP":1},"content_text":"5月23日，Armata Pharmaceuticals, Inc.（ARMP.US）公布财报，公告显示公司2025财年第一财季净利润为-6.53百万美元，同比增加73.90%；其中营业收入为491000.00美元，同比减少49.17%，每股基本收益为-0.18美元。从资产负债表来看，Armata Pharmaceuticals, Inc.（ARMP.US）总负债1.41亿美元，其中短期债务1.07亿美元，资产负债比为61.88，流动比率为11.87。机构评级：截至2025年5月23日，当前有1家机构对Armata Pharmaceuticals, Inc.目标价做出预测，其中目标均价为9.00美元，其中最低目标价为9.00美元，最高目标价为9.00美元。公司简介：Armata Pharmaceuticals Inc 是一家病原体特异性噬菌体疗法的开发商，利用其专有的噬菌体技术来治疗抗生素耐药性和难以治疗的细菌感染。该公司正在开发和推进一系列天然和合成噬菌体候选药物，包括铜绿假单胞菌、金黄色葡萄球菌和其他病原体的临床候选药物。此外，该公司正在与默克合作，开发专有的合成噬菌体候选物，以针对未公开的传染病病原体。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2537147923","isCrawlerRequest":true}